Skip to main content

Table 6 MSI status associated with immunotherapy response in gastric cancer patients

From: Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients

Response

Total No.

MSS/MSI-Low

MSI-High

P

PD

24

24

0

 

SD

79

76

3

 

PR

18

15

3

 

CR

1

1

0

 

ORR

15.6% (95% CI: 9.0-22.1%)

13.8% (95%CI: 7.4-20.2%)

50% (95% CI: -7.5-107.5%)

0.048

DCR

80.3% (95%CI: 73.2-87.5%)

79.3% (95%CI: 71.8-86.8%)

100% (95%CI: 100.0%-100.0%)

0.214

  1. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; DCR: disease control rate; ORR: objective response rate; MSI: microsatellite instability
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us